NERV — Minerva Neurosciences Share News
0.000.00%
Last trade - 00:00Brief: Minerva Neurosciences Announces Listing Transfer To Nasdaq Capital Market
U.S. STOCKS ON THE MOVE-Ecoark, Akero, Apple
U.S. STOCKS ON THE MOVE-Annovis Bio, Helbiz, SuperCom
U.S. STOCKS ON THE MOVE-Centennial, La-Z-Boy, SciSparc
U.S. STOCKS ON THE MOVE-Farfetch, Energy firms, Intuit Inc
Minerva Neurosciences jumps after hedge fund reveals stake
Brief: Point72 Asset Management Lp Reports 8.8% Passive Stake In Minerva Neurosciences Inc As Of August 22 - SEC Filing
U.S. STOCKS ON THE MOVE-Macy, Tritium, Ares Management
U.S. STOCKS ON THE MOVE-Energy firms, Natgas companies, ProPetro
H.C. Wainwright remains cautious on Minerva's application for schizophrenia treatment, cuts PT
U.S. STOCKS ON THE MOVE-Minerva, Cano Health, United Maritime
U.S. STOCKS ON THE MOVE-Minerva, Akili, Pharvaris
Minerva up on seeking FDA approval for schizophrenia treatment
Brief: Minerva Neurosciences Submits New Drug Application To FDA For Roluperidone For Treatment Of Negative Symptoms In Patients With Schizophrenia
Brief: Minerva Neurosciences Submits New Drug Application To FDA For Roluperidone For Treatment Of Negative Symptoms In Patients With Schizophrenia
Brief: Minerva Neurosciences Posts Q2 Loss Per Share $1.63
Minerva Neurosciences Inc reports results for the quarter ended in June - Earnings Summary
Minerva Neurosciences Inc expected to post a loss of $1.65 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Spirit Airlines Inc, Tesla Inc, Kellogg